Date: 2017-04-19
Type of information: Financing round
Company: Synpromics (UK)
Investors: Calculus Capital (UK) Scottish Investment Bank (UK) private shareholders
Amount: £5.2 million
Funding type: financing round
Planned used:
- The majority of the new investment will be used to further develop and exemplify Synpromics proprietary PromPT™ synthetic promoter design platform. PromPT™ enables the design of unique synthetic promoters which give precise control of gene function in many areas of gene medicine including gene therapy, cell therapy and gene editing. The Company is also preparing to move into a larger, new purpose built, facility.
Others:
- • On April 19, 2017, Synpromics announced that it has completed a financing round of £5.2M. Participants included existing investors Calculus Capital, the Scottish Investment Bank, the investment arm of Scottish Enterprise and private shareholders.
Therapeutic area: Technology - Services
Is general: Yes
